BIOLASE (NASDAQ:BIOL) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a note issued to investors on Saturday. The firm set a “sell” rating on the medical technology company’s stock.

BIOL has been the subject of several other research reports. Benchmark reiterated a “speculative buy” rating and issued a $0.40 price target on shares of BIOLASE in a research report on Wednesday, October 2nd. Ascendiant Capital Markets dropped their target price on BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd.

BIOLASE Price Performance

Shares of NASDAQ:BIOL opened at $0.01 on Friday. The firm has a fifty day simple moving average of $0.01 and a two-hundred day simple moving average of $0.06. BIOLASE has a 52 week low of $0.02 and a 52 week high of $1.94. The stock has a market capitalization of $267,256.00, a P/E ratio of 0.00 and a beta of 0.67.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.